COX-2 expression in lobular in situneoplasia of the breast: Correlation with histopathological grading system according to the Tavassoli classification

Histopathology

Volumn 51, Issue 1, 2007, Pages 33-39

  Perrone, G ^a   Zagami, M ^a   Santini, D ^a   Vincenzi, B ^a   Gullotta, G ^a   Morini, S ^a   Battista, C ^a   Guerriero, G ^b   Altomare, V ^a   Tonini, G ^a   Rabitti, C ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast; COX 2; Immunohistochemistry; In situ cancer; Lobular

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER CLASSIFICATION; CANCER GRADING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY;

EID: 34250843343     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02731.x     Document Type: Article

References (37)

1. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985 55 2698 2708.
2. Tavassoli FA. Lobular neoplasia (atypical hyperplasia and lobular carcinoma in situ). In Tavassoli FA ed. Pathology of the breast, 2nd edn. New York : McGraw-Hill 1999 373 400.
3. Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res. 1998 58 4721 4727.
4. Tavassoli FA. Lobular neoplasia. In Tavassoli FA, Devilee P eds. World Health Organization cassification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon : IARC Press 2003 62.
5. Vos CB, Cleton-Jansen AM, Berx G et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br. J. Cancer 1997 76 1131 1133.
6. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994 5 138 146.
7. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996 7 203 205.
8. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br. J. Cancer 2000 83 112 120.
9. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001 1 11 21.
10. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer 2001 8 97 114.
11. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends. Pharmacol. Sci. 2003 24 96 102.
12. Karmali RA, Welt S, Thaler HT, Lefevre F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br. J. Cancer 1983 48 689 696.
13. Liu CH, Chang SH, Narko K et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 2001 276 18563 18569.
14. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000 60 2101 2103.
15. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002 62 1676 1681.
16. Perrone G, Santini D, Vincenzi B et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 2005 46 561 568.
17. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994 107 1183 1188.
18. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997 57 1276 1280.
19. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999 59 198 204.
20. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998 58 4997 5001.
21. Tucker ON, Dannenberg AJ, Yang EK et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999 59 987 990.
22. Ristimaki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002 62 632 635.
23. Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin. Breast Cancer 2004 4 428 433.
24. Fisher ER, Costantino J, Fisher B et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer 1996 78 1403 1416.
25. Bratthauer GL, Tavassoli FA. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch. 2002 440 134 138.
26. Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J. Biol. Chem. 1998 273 9886 9893.
27. Liou JY, Deng WG, Gilroy DW, Shyue SK, Wu KK. Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts. J. Biol. Chem. 2001 276 34975 34982.
28. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. J. Biol. Chem. 1998 273 5419 5422.
29. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995 55 2556 2559.
30. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995 83 493 501.
31. Oshima M, Dinchuk JE, Kargman SL et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 87 803 809.
32. Vane JR, Mitchell JA, Appleton I et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc. Natl Acad. Sci. USA 1994 91 2046 2050.
33. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl Acad. Sci. USA 1994 91 12013 12017.
34. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 1999 5 698 701.
35. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc. Natl Acad. Sci. USA 1996 93 6448 6453.
36. Shaul PW, Smart EJ, Robinson LJ et al. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem. 1996 271 6518 6522.
37. Anderson RG. The caveolae membrane system. Annu. Rev. Biochem. 1998 67 199 225.